Index

Note: Page numbers followed by italicized f’s and t’s indicate figures and tables, respectively.

Abacavir, 143, 150–51
Abbey Pain Scale, 321
Abciximab, 79
Abdominal injuries
  in abused children, 285
  screening for, 286
  blood tests, 286
  imaging, 286
  in geriatric trauma patients, 242
Abdominal pain
  chronic, 328–33
  in dialysis patients, 82–3
  lower quadrant, 60, 61f
Abusive head trauma (AHT), 272
ABVD therapy for Hodgkin’s lymphoma, 167
Acetaminophen, 334
N-acetylcysteine, 174
Acidosis, in dialysis patients, 84–5
Acute chest syndrome, 125–8, 128f
Acute coronary syndrome
  in HIV-positive adults, 144
  in obese patients, 205–6, 207f
Acute kidney injury (AKI), in renal transplant patient, 56–7, 58t
Acute lymphoblastic leukemia (ALL), 161t, 310
Acute megakaryoblastic leukemia (AML), 161t, 310
Addiction, 321
Adult congenital heart disease (ACHD)
  patients. See also Congenital heart disease (CHD)
  considerations for, 27
  in ED, 26
  epidemiology of, 26
  mistakes during treatment of, 27f
  symptoms and findings missed or inadequately treated in, 27f
Advanced Cardiovascular Life Support (ACLS), 5
Advanced Trauma Life Support course, by the American College of Surgeon, 243
Air filter, use of, 38
Airway clearance therapies, 98, 100
Airway management
  in geriatric trauma patient, 233–4
  in obese patients, 214–15
Alcohol ingestion, in geriatric trauma patients, 231–2
Alopixadronate, use of, 106–7
Alkylating agents, 163f
Allodynia, 322
Alloimmunization, 133
Allopurinol therapy, 172
Alosetron, 330
American Association on Intellectual and Developmental Disabilities, 299
American Heart Association (AHA), 5
Ampicillin–sulbactam, 257
Anemia, in sickle-cell patients
  approach to, 124–5
  hemoglobin level, decrease in, 123
  hemolytic complications, of SCD aplastic crisis, 124
  hyperhemolysis syndrome, 124
  transfusions in ED, 123–4
Angiogenesis, targeting of, 178
Anthracyclines, 163, 168
extravasation, 175–6, 176f
Anticoagulation, effect on trauma outcomes, 236–7
Antidotes, development of, 177
Antilymphocyte agents, for induction therapy, 54
Antimetabolites, 163
“Antimicrobial-locking” of catheters, use of, 92
Anxiety, in cystic fibrosis, 108
Aplastic crisis, 124
Aprepitant, 174
Aquagenic wrinkling, early, 109
Arrhythmias
in patients with CCTGA, 42
in patients with repaired TOF, 39
Arterial base deficit, 234
Arterial occlusion, 131
Arterial-switch operations (ASO), 41
Atrial baffle procedures, 40–41, 40f complications of, 41
Atrial septal defect (ASD), 28, 29t description of, 28
epidemiology of, 28
examination of adults with, 28, 31
symptoms in adults, 28, 29t
treatment for, 31
types of, 28
Atripla, 152
Autoimmune thyroid disorder, 150
Azathioprine, 53, 54–56f
Azithromycin, 64, 97f, 98

Back pain, low, 325–7
Bacterial folliculitis, 150
Bacterial infections, after transplantation, 264–5
Bariatric surgical procedures, 184
biliopancreatic diversion/duodenal switch, 185, 186f, 187
complications, diagnosis and treatment of, 187–98. See also specific procedure
future perspective on, 198–9
laparoscopic adjustable gastric banding, 185, 186f
Roux-en-Y gastric bypass, 185, 186f
sleeve gastrectomy, 185, 186f
vertical banded gastroplasty, 186f, 187
Benadryl, 327
Benzodiazepines, 108, 234
Bevacizumab (Avastin), 165, 178
Bilevel Positive Airway Pressure (BiPAP), 100
Biliopancreatic diversion/duodenal switch (BPD/DS) complications of, and treatment, 197–8
procedure of, 185, 186f, 187
Bite marks, 278, 278f
β-lactam antibiotic, 99
Bladder cancer, 160t
Bleomycin, 167, 170–71
Blood transfusion, in oligo-anuric dialysis patient, 92
Body habitus effect, on elderly trauma patient, 230
Bolus fluid therapy, 255
Bortezomib (Velcade), 165t
Brain cancer, 160t
Brain natriuretic peptide (BNP), 128 level in dialysis patient, 80
Breast cancer, 160t
Brief Pain Inventory (BPI), 322
Bronchial artery embolization, 102
Bronchiolitis obliterans organizing pneumonia (BOOP), 170
Brussels, 277–8
Burkholderia cepacia complex, in cystic fibrosis patients, 99–100
Burns injuries, in elderly patients, 239–40
Cacalol, 178
Calcineurin inhibitors (CNIs), 52–3, 66, 68
Calciphylaxis, 90
Calcium channel blockers, 330
Calcium phosphate crystals, 259
Canadian C-spine rule, and trauma patients, 235
Cancer, 158
American Cancer Society data on, 158
chemotherapy for treatment of, 158
epidemiology of, 158
hematological malignancies,
chemotherapeutic regimens for, 161
mechanisms of action and side effects of targeted therapies in, 164–5
patients, challenges in management of, 158–9. See also Cancer patients, receiving chemotherapy
skin and bone cancers,
chemotherapeutic regimens for, 162
solid tumors, chemotherapeutic regimens for, 160
World Health Organization data on, 158
Cancer patients, receiving chemotherapy
antidotes, development of, 177
ED evaluation of, 159–61
chemotherapeutic regimen, identification of, 159. See also Cancer
date of last chemotherapy session, 159
hypersensitivity-related concerns, 161
future perspective on, 177–8
side effects of chemotherapeutic agents in altered mental status, 166
cardiac, 168–70
central nervous system toxicity, 167–8
cerebrovascular accidents, 168
dermatologic, 175–6
electrolyte abnormalities, 172–3
gastrointestinal, 173–4
hematologic, 171
neurologic complications, 162
pulmonary, 170–71
renal, 174–5
reproductive system, 176–7
seizures, 166
sensory changes, 166–7
tumor lysis syndrome, 171–2
Carafate, 194
Cardiac arrest, 5
care of patients in, 5
causes of death for patients after, 6–7
epidemiology and pathophysiology of, 6–8
out-of-hospital, 6–7
treatment after. See Post-cardiac arrest care
Cardiac death, 6
Cardiac history, use of, 27
Cardiac side effect, of chemotherapy, 168–70
Cardiomyopathy, 168–9
in HIV-positive adults, 144
Cardiovascular diseases in cystic fibrosis, 107–8
in dialysis patient, 79–80
in elderly trauma patient, 231
in renal transplant recipients, 63
in SCD, 129–30
Caspofungin, 260
Cation-exchange resin, 86
Cefazolin, 262
Cellulitis, 263
Central nervous system toxicity, 167–8
Central venous catheters, 252–3
complications related to line infection, 259–60
line occlusion, 258–9, 258t
Cerebrovascular accidents (CVA), chemotherapy and, 168
Cervical spine fractures, in elderly, 235–6
Cervix cancer, 160t
Cetuximab, 164t
Child abuse
abusive head trauma as form of, 272
children-mandated reporting in, 288
definition of, 271
and disposition, 290
Index 345

future perspective on, 290–91
incidence of, 272
physical abuse, 272–3
red flags for, 274:
role of emergency physician in, 274–5
screening studies for, 283, 283:
abdominal injuries, 285–6
neuroimaging, 284–5
retinal examination, 285
siblings and contacts, 286
skeletal survey, 283–4
signs and symptoms, 275
bite marks, 278
bruises, 277–8
burns, 278–9
demographic factors, 275–6
fractures, 280–81, 280:
head injuries, 280
historical red flags, 276
myth about, 281–2
oropharyngeal injuries, 279–80
physical examination red flags, 276

treatment for, 288
Child Protective Services (CPS), 274, 288
Cholelithiasis/cholecystitis, 255, 257
Cholestasis, 255
Chronic allograft nephropathy (CAN), 57
Chronic hypoxemia, in cyanotic CHD patients, 35
gastrointestinal system, effect on, 38
hematologic abnormalities in, 35, 38
musculoskeletal systems, effect on, 38
renal abnormalities in, 38
Chronic kidney disease (CKD), in renal transplant patient, 57
Chronic obstructive pulmonary disease (COPD)
in elderly, 229–30
in obese patient, 212
Chronic pain, 319
assessment of, 320–22
conditions causing, management of abdominal pain, 328, 332–3
back pain, 325–7
chronic pain in geriatric patient, 333–5
chronic pelvic pain, 331–2
chronic post-operative abdominal pain, 332
headaches and migraines, 327–8
irritable bowel syndrome, 330–31
pancreatitis pain, 328–30
disability for patient with, 322
future perspective on management of, 335–6
multimodal therapy for, 323–5
opioid analgesia in ED, 324, 324:
route of administration, 323
side effects of opioids use, 324–5
physiologic state of patient with addiction, 321
dependence, 321
pseudoaddiction, 321
withdrawal state, 321
visits to ED in, 319–20
Chronic pelvic pain (CPP), 331–2
female, 331
male, 331
Chronic rejection, development of, 267
Ciprofloxacin, 108
Cisplatin, 166–7
Classic metaphyseal fracture, 280, 280:
CLL, 161:
Clock-watcher, 120
Clonidine, 330
Clostridium difficile
diarrhea in HIV positive adults on HAART, 148
in patients with cystic fibrosis, 103–4
CML, 161:
CNS reperfusion injury, 7
Coarctation of the aorta, 30, 33–4
chest X-ray findings in, 34
complications after repair of, 34
ECG findings in, 33–4
interventional therapy for, 34
physical exam of adult with, 33
recurrence of, 34
surgical therapy for, 34
symptoms in adults, 33
346  Index

Colorectal cancer, 160t
Complete transposition of the great arteries (TGA), 36t, 39–41.
See also d-TGA
Congenital heart disease (CHD), 26
in adults, 26
children with, 26
and chromosomal abnormalities, in intellectually disabled, 305t
cyanotic defects, clinical implications of, 35, 36t–37t
complete transposition of the great arteries, 36t, 39–41
congenitally corrected transposition of the great arteries, 37t, 42–3
Ebstein’s anomaly, 37t, 43–4
late complications of cyanotic lesions, 35, 38
tetralogy of Fallot, 36t, 38–9
tricuspid atresia, 37t, 44–6
definition of, 26
epidemiology of, 26
and future perspective, 47
non-cyanotic, clinical implications of, 29t–30t
atrial septal defect, 28, 29t, 31
coarctation of the aorta, 30t, 33–4
patent ductus arteriosus, 30t, 32–3
ventricular septal defect, 29t, 31–2
other considerations in ACHD patients
endocarditis, 46–7
non-cardiac surgery, 46
psychiatric illness, 46
Congenital heart disease center, referral to, 27
Congenitally corrected transposition of the great arteries (CCTGA), 37t, 42–3
complication associated with, 42
physical exam of patient with, 42
treatment of, 42–3
Congestive heart failure, in obese patients, 206–8
Constipation, in intellectually disabled, 307
Continuous ambulatory PD (CAPD), 75
Continuous cycling PD (CCPD), 76
Contrast-induced nephropathy (CIN), 235
Cord compression, 162
Cor pulmonale, in cystic fibrosis, 107
Corticosteroids, 53, 54t, 55t
for acute chest syndrome, 126
use in pulmonary exacerbations, 100
CT coronary angiography (CTCA), 206
CT imaging, for geriatric trauma patient, 235
Cushion effect, 210
Cyclosporine, 53, 54t–56t
Cyclooxygenase-2 (COX2) inhibitors, 329
Cystic fibrosis, 96
in adulthood, 97. See also Cystic fibrosis patients
diagnosis of, 96–7
emerging therapies for, 110t
epidemiology of, 96
future perspective on treatment of, 109–10
life expectancy in, improvements in, 96
mutations in CFTR gene in, 96
Cystic Fibrosis Foundation National Data Registry, 96
Cystic fibrosis patients, 97
chest pain in, 107–8
cor pulmonale in, 107
dermatologic disease in, 108–9
diabetes in, 106
gastrointestinal complications of, 102–3
gastrointestinal disease, 103–4
hepatobiliary disease, 105
pancreatic disease, 104–5
hypoglycemia in, 106
musculoskeletal and rheumatic disease in, 106–7
ophthalmic disease in, 109
psychiatric illness in, 108
pulmonary disease in, 97–102
hemoptysis, 101–2
and infection control procedures, 101
maintenance medications for, 97, 98
microbiologic flora from respiratory tract, 99
pneumothorax, 102
pulmonary exacerbations, 98–101
and use of airway clearance therapies, 98
rhinosinusitis in, 108
Cystic fibrosis related diabetes mellitus (CFRD), 106
Cytomegalovirus (CMV) infection after transplantation, 265–6
in renal transplant patients, 61–2
Cytopenias, medication-associated, 66, 67
Dasatinib (Sprycel), 165
Deep vein thrombosis (DVT), 108, 170
catheter-related, in children, 259
Dehydration, in pediatric intestinal failure patient, 253–4
diagnosis of, 254
history and physical examination in, 254
laboratory evaluation and management of, 254
Dialysis patients
abdominal pain in, 82–3
anemia in, 83
articular and musculoskeletal problems in, 90
calciphylaxis in, 90
chest pain in, 79–80
diabetes-related emergencies in, considerations in, 87–8
diagnostic tests and medications in, choice of, 90–92
dose-adjustment for medications in, 91
dyspnea in, 80–81
in ED, factors for, 74
ESRD-associated hyperphosphatemia in, 86
ESRD-associated hypocalcemia in, 86
fever in, 76
evaluation and management of, 76–8, 77t, 78t
febrile HD patients, 76–7, 77t
PD-associated peritonitis, 77–8, 78t
future perspective on, 92
with gastrointestinal bleeding, 82
HD vascular access in ED, considerations in, 89
hypercalcemia in, 86
hyperkalemia in, 85–6
hypermagnesemia in, 87
hypertensive urgency/emergency in, 81–2
hypokalemia in, 87
hyponatremia in, 87
hypophosphatemia and hypomagnesemia in, 87
hypotension in, 81
intra-dialytic accidents related emergencies in, 89–90
neurological complaints in, 83–4
syncope in, 81
Diabetes mellitus
and elderly trauma patient, 230–31
in HIV positive adults on HAART, 150
in renal transplant recipients, 69
Dialysis disequilibrium, 83–4
Delirium, 166
in geriatric trauma patients, 232
Dementia, in elderly, 230
Denulosol, 110
Depression, in cystic fibrosis, 108
Dermatologic diseases
in chemotherapy patients, 175–6, 176
in cystic fibrosis, 108–9
in HIV-positive adults on HAART, 150–51
Dexrazoxane, 168–9, 175–6, 176
Index

Dialysis patients (Continued)
uremic, high anion-gap metabolic acidosis in, 84–5
urinary tract related problems in, 88–9
Dialysis therapy, principles of, 75–6, 75 f, 76 f
Diclofenac, 326
Dicyclomine, 330
DiGeorge syndrome, 38, 305, 305 t
Distal intestinal obstructive syndrome (DIOS), 103–4, 104 f
Down Syndrome (Trisomy 21), 302
Atrio–ventricular canal defects in, 304–5
gastrointestinal disorders in, 308
hematologic disorders in, 310
hypothyroidism and obesity in, 308
Doxorubicin, 169
d-TGA
adults with, 40
arterial-switch operations for, 41
infants with, 40
meaning of, 40
Mustard and Senning procedures for, 40–41, 40 f
Dyspnea in dialysis patients, 80–81
Eastern Association for the Surgery of Trauma Guidelines for Geriatric Trauma care, 243
Ebstein’s anomaly, 37 t, 43–4
abnormalities with, 43
causes of death in adults with, 43
physical exam of patient with, 43
treatment for, 43–4
Education for the Handicapped Act, 300
Efavirenz, 143 t, 150
Embeda, 335
Embolization, for hemoptysis, 102
Emergency department (ED), 1. See also specific topics
and complications of social pathologies, 3–4
emergency physicians challenges faced by, 1–2
complications of new therapies, knowledge of, 3
increased longevity and considerations for, 2–3
visits to, 1
Emergency medical services (EMS), 233
Emesis, 173
Encephalopathy, 257–8
Endobarrier®, 199
Endocarditis, in patients with CHD, 45–6
End of life care, of geriatric trauma patient, 238
End-stage renal disease (ESRD), 51, 74
dialysis for, 74
increase in, 74
renal transplantation for, 51
Enoxaparin, 79
Enteral feeding devices, 253
complications associated with, 260
gastric outlet obstruction, 262
gastric ulceration, 262
gastrostomy tube dislodgement, 260–61
obstruction and leakage, 262
stoma site complications, 262–3, 263 f
Enteric coated peppermint capsules, 330
Enterobius vermicularis infection, in intellectually disabled, 307
Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKI), 178
Epstein–Barr virus (EBV) infection, after transplantation, 265–6
Eptifibatide, 79
Erlotinib (Tarceva), 164 t, 178
Erythrocytopenia, 125–7, 130–31
Erythrocytosis, 67, 67 t
in cyanotic CHD patients, 35
Esophageal cancer, 160 t
Esophageal variceal bleeding, 257
ESRD-associated hyperphosphatemia, 86–7
Index 349

ESRD-associated hypocalcemia, 86
Ethanol solution, 259
Etomidate, 234
Etoposide, 171
Everolimus, 54–56
Ewing’s sarcoma, 162
Extremity fracture, in elderly patients, 243
Face, Legs, Activity, Cry and Consolability (FLACC) observational scale, 321
Falls, in geriatric patients, 238
Family violence, 271. See also Child abuse and Intimate partner violence (IPV)
emergency physicians, role of, 271–2
epidemiology of, 271–2
Fenobam, 314
Fen-Phen, 219
Fentanyl, 324
Fetal-Alcohol Syndrome, 302
Fever
in dialysis patient, 76–8, 77t, 78t
in renal transplant recipients, 61–3, 62t
in sickle-cell patient, 122
approach to, 122–3
causes for, 122
Fingertip bruising, 278
Fistula first initiative, 92
Fluoroquinolones, 99
Focal biliary cirrhosis, 105
Foley catheter, 261
Fosfomycin/tobramycin, in cystic fibrosis, 110
Fractures, in children, 280–81, 280f, 281f
Fragile X Mental Retardation Protein (FMRP), 313
Fragile X Syndrome, 313
Fresh frozen plasma (FFP), 236
Functional gastrointestinal disorder (FGID), 328
Functional pain, 322
Fungal central venous catheter infections, 260
Gallstones, in cystic fibrosis patients, 105
Gastric cancer, 160t
Gastric outlet obstruction, 262
Gastric ulceration, 262
Gastroesophageal reflux disease, 307
Gastrograffin, 103
Gastrointestinal disorders in chemotherapy patients, 173–4
in cystic fibrosis patient, 102–5, 103f
in HIV-positive adults on HAART, 147–9
in renal transplant recipients, 65, 65t
Gastrointestinal hemorrhage in ESRD patient, 82
Gastrostomy tube dislodgement, 260–61
Gefitinib (Iressa), 164t, 178
Gemtuzumab ozogamicin (Mylotarg), 164t
Geriatric Education for EMS course, 243
Geriatric patient, chronic pain in, 333–5
Geriatric trauma patients, 228
body habitus in, 230
cardiovascular disease in, 231
chronic obstructive lung disease in, 229–30
delirium in, 232–3
dementia in, 230
depression and suicidal ideation in, 232
diabetes mellitus in, 230–31
discharge from ED, 237, 237t
ED management of
airway management, 233–4
anticoagulation medications, assessment of, 236–7
imaging evaluation, 235–6
need for resuscitation, determination of, 234–5
physical examination, 235
prehospital management, 233
vital signs assessment, 234
end of life care of, 238
epidemiology of, 228
future research on, 243–4
Geriatric trauma patients (Continued)
mechanisms of trauma and injury patterns in
blunt abdominal trauma, 242
burns, 239–40
evertebral fracture, 243
falls, 238
lacerations, 243
motor vehicle accidents, 238–9
pedestrian struck, 239
penetrating trauma, 242
rib fracture, 242
spinal fracture, 241–2
subdural hematoma, 240–41, 240
medications affecting ED evaluation in, 231, 232
and younger trauma patients, comparison of, 228–9
Germ cell of testes, 160
Glucarpidase, 175, 177
Gout, 68
Graft rejection, 266
Granulation tissue, at site of gastrostomy stoma, 263, 263
Graphical or picture scales (GRS), 321
HAART. See Highly active antiretroviral therapy (HAART)
Headaches, 327–8
Hearing loss, chemotherapeutic agents and, 166–7
Heart transplantation, for CHD, 47
Hematologic complications in chemotherapy patients, 171
in renal transplant recipients, 66–7, 67
Hemodialysis (HD), 74
accesses used for, 75f
home, 75
in-center, 75
infection of HD access, 76–7
microbiology of, 77f
recommended initial antibiotic therapy for, 77f
procedure of, 75
Hemolytic index, 116
Hemolytic-uremic syndrome (HUS), 66, 67f
Hemoptysis, in cystic fibrosis patients, 101–2
Hemorrhagic cystitis, 175
Hepatobiliary complications, with intestinal failure, 255
cholelithiasis and cholecystitis, 255, 257
encephalopathy, 257–8
esophageal variceal bleeding, 257
Hepatobiliary disease, in cystic fibrosis patients, 105
Hepatocellular cancer, 160t
Highly active antiretroviral therapy (HAART), 141
first-line regimens, 142
initiation of, 142
HIV-nephropathy, 145
HIV-positive adults on HAART, 141
cardiovascular diseases in, 144
dermatologic diseases in, 150–51
endocrine disease in, 150
epidemiology of, 141–2
future perspective on, 152–3
gastrointestinal disease in, 147–9
HAART regimens, 142
HAART side effects in, 143, 143f
class side effects of antiretroviral medications, 143f
side effects of HAART medications, 143f
hematologic and oncologic diseases in, 149
immune reconstitution inflammatory syndrome, 147
life expectancy in, 141
medication interactions of relevance in ED, 144
musculoskeletal diseases in, 151–2
neurological disorders in, 146–7
ocular diseases in, 151
psychiatric disorders in, 150
pulmonary disease in, 144–5
renal disease in, 145–6
Hodgkin’s lymphoma, 161t
Hungry bone syndrome, 86
Hydromorphone, 324t
Hyperalgesia, 120, 322
Hyperbilirubinemia, 267
Hypercalcemia, in dialysis patients, 86
Hyperhemolysis syndrome, 124
Hyperkalemia, in HD patients, 85
Hypermagnesemia, in HD patients, 87
Hypertension, in dialysis patients, 81–2
Hypertensive encephalopathy, 84
Hypertonic saline, use in cystic fibrosis patients, 97, 100
Hypertrophic osteoarthropathy, 38
Hypertrophic pulmonary osteoarthropathy, 107
Hyphema, 130
Hyponatremia, 172–3 in ESRD patients, 87
Hypotension in dialysis patients, 81
Ibritumomab tiuxetan (Zevalin), 164
Imaging evaluation, in geriatric trauma patient, 235–6
Imatinib (Gleevec), 165
Immune reconstitution inflammatory syndrome (IRIS), 147
Immune therapy, 163
Incentive spirometry, 126
Incontinence of bowel, in intellectual disability, 309
Induced therapeutic hypothermia (ITH), use of, 7. See also
Post-cardiac arrest care after out-of-hospital cardiac arrest, 7
barriers to use of, 7–11, 9f
for neuroresuscitation, 14–17, 16f
endovascular cooling, 15
infusion cooling, 15–16
surface cooling, 15
trials on, 7
Inflammatory pain, 322
Insulin-like growth factor 1 (IGF-1), 167–8
Insulin therapy, 106
Integrase strand transfer inhibitor, 142
Intellectual disability, 299
causes of, 301–2, 301f
environmental, 302
 genetic, 302
infectious, 302
metabolic, 302
traumatic, 302
definition of, 299
future perspective on treatment of, 313–14
incidence of, 299
longevity in, increase in, 300
management of, in ED informed consent, 312–13
laboratory evaluations, 312
patient history, obtaining of, 311
physical examination, 311–12
physician–patient communication, 310–11
organ system-based pathologies in, 302
cardiac, 304–7
ear, nose, and throat, 304
endocrine, 308
gastrointestinal, 307–8
genitourinary and gynecologic, 308–9
hematology and oncology, 310
musculoskeletal, 309–10
neurology, 303
pharmacology, 310
psychiatry, 303
pulmonary, 307
perception of, changes in, 299–300
prevalence of, 299
Intensive insulin therapy, 231
International Liaison Committee on Resuscitation (ILCOR), 5
International Normalized Ratio (INR), 236
Interstitial cystitis/bladder pain syndrome (IC/BPS), 332
Intestinal failure, 251. See also Intestinal transplantation complications in pediatric patients
 altered fluid and electrolyte balance, 253–4, 254f
central venous catheters related, 258–60
 gastrostomy tubes related, 260–63
hepatoiliary complications, 255, 257–8
intestinal obstruction, 255, 256f
definition of, 251
352  Index

Intestinal failure (Continued)
diagnoses leading to, 252f
future perspective on, 266–7
incidence and prevalence of children with, 251–2
surgical/procedural interventions in abdominal surgery, 253
central venous catheters, 252–3
enteral feeding devices, 253
visits to ED in, 252
Intestinal obstruction, 255, 256f
Intestinal transplantation, 252, 264
bacterial infections, evaluation for, 264–5
care of patient with, 264–6
future perspective on, 267
graft rejection in, 266
infection after, 264
viral infections, evaluation for, 265–6
Intimate partner violence (IPV), 271
definition of, 271
and disposition, 290
future perspective on, 291
health consequences of, 273
National Violence Against Women survey on, 273
role of emergency physician in, 275
screening tools for, 287–8, 287f
signs and symptoms, 282
treatment for, 288–90
USPSTF recommendations on, 287
visits to ED in, 273
women’s health, impact on, 273
Intra-dialytic complications, during hemodialysis, 89–90
Intramuscular injections, 323
Intravenous sodium bicarbonate therapy, in dialysis patients, 85
Ion channel modulators, 110
IPV. See Intimate partner violence (IPV)
Irritable bowel syndrome (IBS), 330–31
JC virus, and IRIS, 147
Joint contractures, in intellectual disabled, 309
Kaposi’s sarcoma, 162f
Ketamine, 312
Kidney stones, by atazanavir, 146
Klinefelter Syndrome, 305f
Lacrations, in elderly patients, 243
Lactate levels, 234
Lactic acidosis, 152
Lactulose, 257–8
LAGB. See Laparoscopic adjustable gastric banding (LAGB)
Lantus, 106
Laparoscopic adjustable gastric banding (LAGB), 188
advantages of, 188
complications of, and treatment
early post-operative obstruction, 188
gastric erosion, 189–90
gastric prolapse (slip), 188
LAGB port/tubing complications, 190
tubing breaks, 190
normal LAGB, 189f
procedure of, 185, 186f
slipped LAGB, 189f
Laparoscopic longitudinal (sleeve) gastrectomy (LSG)
complications of, and treatment, 195–7
bleeding from staple line, 195–6
staple line dehiscence, 196–7
stricture formation, 197
procedure of, 185, 186f
Lead poisoning, 302
Lean body weight calculators, 217
Leg ulcers, sickle-cell patient with, 132–3
Lens transparency, in cystic fibrosis, 109
Leukocytosis, 67, 67f
Levofloxacin, 122
Linear bruising, 277
Line-lock therapy, 266
Liposomal amikacin, 110
Liver disease, in HIV positive adults on HAART, 148–9
Lorazepam, 132
Low molecular weight heparin (LMWH), 170
L-transposition of the great arteries. See Congenitally corrected transposition of the great arteries (CCTGA)
Lumbar puncture depth, formula for, 216
Lung cancer, 160t
Lung resection, 102
Lymphoceles, 60
Macrolide antibiotics, 64, 125
Maintenance immunosuppressive medications, for renal transplant recipients, 52–3, 54t
adverse effects of, 55t
drug interactions with, 56t
Marlex band, 187
Meconium ileus equivalent. See Distal intestinal obstructive syndrome (DIOS)
Melanoma, 162t
Mental retardation. See Intellectual disability
Mental status, alteration in, 166
MESNA (2-Mercaptoethane sulfonate sodium), 175
Methicillin-resistant strains (MRSA), respiratory infection by, 99
Methotrexate toxicity, 171
Metoclopramide, 303
Metronidazole, 104
Mic-key button gastrostomy tube, 261f
Microtubular agents, 163t
Midazolam, 234
Migraines. See Headaches
Mirtazapine, 108
Mixed venous oxygen saturation, 235
Monoclonal antibody therapy, 159, 178
Morphine, 324t
Motor vehicle accidents, elderly drivers and, 238–9
Mucositis, 174
Multiple myeloma, 161t
Musculoskeletal diseases in HIV-positive adults on HAART, 151–2
in renal transplant recipients, 67, 68t
Mustard and Senning procedures, for d-TGA. See Atrial baffle procedures
Mycobacterium tuberculosis, and IRIS, 147
Mycophenolate mofetil, 53, 54t, 55t
Mycophenolate sodium, 53, 54t, 55t
N-acetylcysteine, oral, 110
National Domestic Violence Hotline, 289
National Expert Panel on Field Triage, 233
National Household Travel Survey, 238
Natural orifice surgery (NOTES), 199
Nephrotoxicity, from chemotherapeutic agents, 174–5
Neuroimaging, for abusive injuries, 284–5
Neurokinin-1 receptor antagonists, 173
Neuroleptic medications, 303
Neurological death, 6
Neurological disorders, in HIV-positive adults on HAART, 146–7
Neurologic complications, of chemotherapeutic regimen, 162
Neuropathic pain, 322
Neutropenia, 149, 171
Nevirapine, 143
NEXUS criteria, in trauma patients, 235
Nociceptive pain, 322
Non-Hodgkin’s lymphoma, 161t
Noninvasive positive pressure ventilation (NPPV), 208, 211–12
Non-nucleoside analog reverse transcriptase inhibitor (NNRTI), 142, 143t, 144
Nonsteroidal anti-inflammatory drugs (NSAIDs), 31, 38, 147, 327, 334 topical, 323–4
Nucleoside analog reverse transcriptase inhibitors (nRTI), 142, 143t
Index

Numerical rating scales (NRS), 321

Nutrient deficiency dermatitis, of cystic fibrosis, 109

Obese patients
acutely coronary syndrome in, 205–6
congestive heart failure in, 206–8
future studies on, 218–19
impediments to management of, in ED
airway management, 214–15
drug dosing, 217–18
lumbar puncture, 216
needle and tube thoracostomy, 217
patient weight estimation, 213–14
vascular access, 216
infection and sepsis in, 213
pulmonary disease in, 211–12
asthma, 211–12
chronic obstructive pulmonary disease, 212
obesity hypoventilation syndrome, 212
obstructive sleep apnea, 212
and sociologic and medicolegal risks, 218
trauma in, 208–9
initial evaluation and imaging in, 210
injury patterns in, 209–10
venous thromboembolism in, 208

Obesity
definition of, 204
epidemiology of, 204
in intellectually disabled, 308
medical co-morbidities associated with, 184
National Health and Nutrition Examination Survey on, 184
physiology of obese patients, 204–5.
see also Obese patients
prevalence of, 184
surgical treatment of, 184. see also Bariatric surgical procedures

Obesity hypoventilation syndrome (OHS), 212

Obesity paradox, 208

Obstructive sleep apnea (OSA), 212

Octreotide, 330

Ocular complications, in SCD
approach to, 131
arterial occlusion, 131
hyphema, 130
vitreous hemorrhage, 130–31

Ofatumumab, 178

Ophthalmic disease
in cystic fibrosis, 109
in HIV-positive adults on HAART, 151

Opportunistic central nervous system (CNS) infection, in renal transplant recipients, 66

Oropharyngeal injuries, in children, 279, 279f

Orphenadrine, 326

Osteonecrosis, 152

Osteoporosis, in intellectual disability, 309

Osteosarcoma, 162

Ovarian cancer, 160

Over-the-counter (OTC) medications, for obesity, 219

Oxybutinin, 332

Paclitaxel, 167, 169, 177

Pain Assessment IN Advanced Dementia (PAINAD) scale, 321

Pain, in sickle-cell disease, 119
approach to, 121–2
criteria for admission, setting of, 121
ED visits for, 119
medical mistake by staff in, 119–20
pain management practices, disparities in, 120
patient’s sickle-cell history and, 121
psychology of pain in, 121

Pain intensity numerical rating scale (Pain-NRS), 323

Pain management, in ED, 319–20,
320t. see also Chronic pain

Palmar–plantar syndrome, 176

Pancreas cancer, 160t
Index

Pancreatic disease, in cystic fibrosis, 104–5
Pancreatitis
acute, in HIV positive adults on HAART, 148
chronic, 328–30
in patients with cystic fibrosis, 104–5
Patent ductus arteriosus (PDA), 30, 32
in adults, 32
diagnosis of, 33
large, ECG in, 32
pathophysiology of, 32
physical exam of adult, 32
treatment for, 33
Patient controlled anesthesia (PCA), 323–4
PDMP Information Exchange (PMIX), 335
Pedestrian struck, 239
Penetrating trauma, 242
Pentosan polysulfate sodium (PPS), 332
Pericardial effusion, in dialysis patient, 79
Peripheral blood culture, 260
Peripheral neuropathy, 167
Peritoneal dialysis (PD), 74
catheter, 75, 76
continuous ambulatory, 75–6
continuous cycling, 76
peritonitis associated with, 77–8
initial management of, 78
microbial spectrum of, 78
recommended initial antibiotic therapy for, 78
Petroleum jelly dressing, 243
Physician–patient communication, improvement in, 311
Piperacillin–tazobactam, 260
Pneumonitis, 171
Pneumothorax, in cystic fibrosis patients, 102
Polyethylene glycol, 103
Polymerase chain reaction (PCR) assay, 62
Polymicrobial peritonitis, 78
Polymyositis, in HIV infection, 151
Polypharmacy complications, in intellectual disability, 310
Post-cardiac arrest care. See also Cardiac arrest
ABCs algorithm for, 10, 11, 17
AHA and ILCOR guidelines on, 5–6
benefits of, 7–8
contraindications to, 7–11, 9
in ED, 11, 17
airway, assessment of, 11–13
appropriate disposition, 17
neuroresuscitation, focus on, 14–17, 16
pulmonary function, evaluation and management of, 13
recommended ED post-cardiac arrest care protocol, 12
systemic and cerebral perfusion, evaluation of, 13–14
emergency medical services and, 17–18
and ethical concerns, 18–19
future perspective on, 19
need of, 5
Post-pericardiotomy syndrome, 31
Post-transplantation lymphoproliferative disorder (PTLD), 265
Pregnancy in SCD, 131–2
Prescription drug management programs (PDMPs), 335
Priapism, 132
Primum ASD, 28. See also Atrial septal defect (ASD)
Propantheline, 334
Prostate cancer, 160
Protease inhibitors, 143
Protein loss enteropathy (PLE), 45
Prothrombin complex concentrate (PCC), 236–7
Pruritus, 325
Pseudoaddiction, 321–2
Pseudomonas aeruginosa first-line therapy for, 99
in patients with cystic fibrosis, 99
tobramycin in treatment of, 98–9
PTC124, in cystic fibrosis, 110
356  Index

Pulmonary complications
  in chemotherapy patients, 170–71
  in HIV-positive adults on HAART, 144–5
  in obese patients, 211–12
  in sickle-cell disease, 125–7
Pulmonary exacerbations, in cystic fibrosis
  diagnosis of, 98–9
  treatment of, 99–101
Pulmonary hypertension in SCD, 126–7
Pulmonary infections, in transplant patients, 63–4
Pulmonary regurgitation, in patients with repaired TOF, 39

Radionuclide bone scans, 284
Rasburicase, 172
Raynaud’s syndrome, 167
Recombinant DNase, 97t, 98
Recombinant factor VIIa, 237
Recombinant tissue plasminogen activator (rt-PA), use of, 259
Refeeding syndrome, 197–8
Renal cell cancer, 160t
Renal disease, in HIV-positive adults on HAART, 145–6
Renal transplantation
  for ESRD, 51
  post-transplant immunosuppression regimens
  adverse effects of maintenance immunosuppressive medications, 55t
  antilymphocyte agents for induction therapy, 54
  discontinuation in antirejection medications, 53–4
  drug interactions with immunosuppressive drugs, 56t
  triple therapy regimen, initial, 52–3, 54t
  surgical anatomy of, 52, 53f
Renal transplant recipients, 51. See also Renal transplantation
  with acute kidney injury (AKI), 56–7, 58t
  cardiovascular disorders in, 63
  chronic kidney disease (CKD) in, 57
  in ED, 51
  electrolyte disorders in, 68–9
  endocrine complications in, 69
  febrile, ED evaluation of, 61–3, 62t
  and future perspective, 69–70
  gastrointestinal disorders in, 65, 65t
  hematologic disorders in, 66–7, 67t
  hypertension-related disorders in, 63
  management of, considerations in, 51–2
  musculoskeletal and articular complaints in, 67–8, 68t
  neurological/psychiatric problems in, 65–6
  respiratory complaints in, 63–4
  surgical complications in, 58
  acute vascular occlusion, 59
  bleeding following biopsy of kidney transplant, 60
  bleeding from or near kidney transplant, 59
  lower quadrant abdominal pain, 60, 61t
  lymphocele, 60
  post-operative complications, generic, 58–9
  transplant renal artery stenosis, 59
  urinary tract obstruction, 60
  urine leak, 59
  urinary tract infection in, 57–8
  Reproductive system, effects of chemotherapy on, 176–7
  Resveratrol, 169
  Rhabdomyosarcoma, 162t
  Rhinosinusitis, in cystic fibrosis, 108
  Rib fractures
    in cystic fibrosis patients, 106
    in elderly trauma patients, 242
  Rice-based meals, 330
  Richmond Agitation and Sedation Scale (RASS), 324
  Rituximab (Rituxan), 164t
  Rocuronium, 234
  Rosiglitazone, 175
Roux-en-Y gastric bypass (RYGBP) complications of, and treatment, 190–95
anastomotic leak, 191–2, 191f
deep vein thromboses (DVT), 192–3
gastrojejunostomy anastomotic stricture, 193
internal hernias, 193–4
marginal ulcers, 194
post-operative bleeding, 192
pulmonary embolism, 193
mineral and vitamin deficiencies, 195
procedure of, 185, 186f

Salmonella osteomyelitis, in sickle-cell patients, 122
Sarcoma, 162t
SCD. See Sickle-cell disease (SCD)
Secundum ASD, 28. See also Atrial septal defect (ASD)
Seizures, 166
in intellectually disabled, 303
Selective serotonin reuptake inhibitors, 108
Sensory loss, in intellectually disabled, 303
Sepsis, in obese patients, 213
Sexual abuse and disorders, in intellectually disabled, 308–9
Shaken baby syndrome, 272
Short gut syndrome, in children, 251. See also Intestinal failure
Siobutramine, 219
Sickle-cell disease (SCD), 115
clinical phenotype of, 116
complications of
acute anemic, 123–5
cardiovascular, 129–30
central nervous system complications, 130
fever/infections, 122–3
ocular, 130–31
pulmonary, 125–8
vaso-occlusive episodes, 119–22
epidemiology of, 115–16
future perspective on treatment for, 134–5
genetics and pathophysiology of, 116–18
hemolysis-endothelial dysfunction subphenotype, 116, 117f
incidence of, 115
leg ulcers in, 132–3
life expectancy in, 118
pregnancy in, 131–2
priapism in, 132
transfusion therapy for, 133–4
viscosity–vaso-occlusion subphenotype, 116, 117f
Sickle-cell trait, 118–19
collapse with exercise in, 119
complications with, 118
risks of, 119
Sickle reticulocytes, 121
Sildenafil, 127
Silicone dressing, 243
Single incision surgery, 199
Single photon emission CT (SPECT) imaging, 206
Sinus venous ASD, 28. See also Atrial septal defect (ASD)
Sirolimus, 53, 54f–56f
Skeletal survey, for abusive injuries, 283–4, 283t
Sorafenib (Nexavar), 165f
Soy-based lipid emulsions, 266
Spinal fracture, in elderly trauma patients, 241–2, 241f
Spinal kyphosis, in cystic fibrosis patients, 106
Steal syndrome, 89
Steatosis, 255
Stevens–Johnson syndrome, 150
Stoma site complications, 262–3
Streptococcus pneumoniae, bacterial pneumonia by, 144–5
Stroke, in sickle-cell patient, 130
Strongyloides stercoralis infection, in intellectually disabled, 307
Subcutaneous administration, 323
Subdural hematoma (SDH) in dialysis patients, 84
in elderly patients, 240–41, 240f
Substance abuse, in geriatric patients, 231–2
Succinylcholine, 234
Suicidal ideation
  in geriatric trauma patients, 232
  in intellectually disabled, 303
Sunitinib (Sutent), 165
Syncope in dialysis patients, 81
Syndrome of inappropriate antidiuretic hormone (SIADH), 172
Systemic atrio–ventricular valve (SAVV), 42
Tacrolimus, 53, 54t–56t, 66
Tegaserod, 330
Temsirolimus, 178
Tenofovir, 143
Tetralogy of Fallot (TOF), 36f, 38–9
  pink tetralogy, 39
  repair of, 38–9
  complications of, 39
  in infants, 39
  physical examination of patient with, 39
  structural abnormalities of, 38
Thalidomide (Thalomid), 165
Thrombocytopenia, 149, 171
Tipranavir, 143
Tobramycin
  in cystic fibrosis, 97t, 98
  in Pseudomonas aeruginosa treatment, 98, 99
Total/partial parenteral nutrition (TPN), 251–2
Tramadol, 334
“Tram-track” appearance of loop marks, 277, 277f
Transfusion therapy, 133–4
  approach to sickle-cell patient in, 134
  dangers of, 133
  formula for estimation of blood transfused, 133
  need of, 133
Transient myeloproliferative disorder (TMD), 310
Transoral gastroplasty (TOGA), 199
Transplant renal artery stenosis, 59
Transplant tourism, 70
Trastuzumab (Herceptin), 164t, 169
Trauma, in obese patients, 208–10
  resuscitation, markers for, 234–5
Tricuspid atresia, 37t, 44–6
  Fontan procedure for, 44, 45f
  complication of, 44–5
  failed, 45–6
Trimethoprim–sulfamethoxazole, 108
Triptans, use of, 327
Tuberculosis, in HIV positive adults on HAART, 145
Tumor lysis syndrome, 171–2
Tunneled catheters, 252–3
Turner Syndrome, 305t, 306
United States Preventive Services Task Force (USPSTF), 287
Uremic pericarditis, 79
Uridine triacetate, 177
Urinary tract infection, in renal transplant patient, 57–8
Urinary tract obstruction, in renal transplant recipient, 60
Urine leak (urinoma), 59
Ursodeoxycholic acid, use of, 105
Vancomycin, 260
Vascular access, in obese patients, 216
Vecuronium, 234
Venous thromboembolism, in obese patients, 208
Ventricular septal defect (VSD), 29t, 31–2
  incidence of, 31
  inlet, 31
  muscular, 31
  perimembranous, 31
  physical exam of adult with, 32
  treatment for, 32
Vertical banded gastroplasty (VBG) complication of, and treatment, 198
  procedure of, 186f, 187
Vinca alkaloids, 163t
### Index

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral infections, after transplantation</td>
<td>265–6</td>
</tr>
<tr>
<td>Visual analog scales (VAS)</td>
<td>321</td>
</tr>
<tr>
<td>Vitamin D deficiency, in intellectual disability</td>
<td>309</td>
</tr>
<tr>
<td>Vitreous hemorrhage</td>
<td>130–31</td>
</tr>
<tr>
<td>VX-770</td>
<td>110</td>
</tr>
<tr>
<td>VX-809</td>
<td>110</td>
</tr>
<tr>
<td>Warfarin use, in geriatric patients</td>
<td>236</td>
</tr>
<tr>
<td>Website, Adult Congenital Heart Association</td>
<td>27</td>
</tr>
<tr>
<td>Williams–Beuren Syndrome</td>
<td>305, 306–7</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>149, 151</td>
</tr>
</tbody>
</table>